Table 1 (a) Characteristics of studies included in the meta-analysis, (b) drug regimens in each study included
Study | Study design | Data sources | Numbers | Patients | Therapy regimen | Follow-up times | Outcomes | NOS scales |
|---|---|---|---|---|---|---|---|---|
(a) | ||||||||
Dawwas GK, 2018 [19] | Retrospective | The Truven Health Market Scan commercial and Medicare Supplement claims databases in the USA between Jan 1, 2014, and Dec 31, 2016 | 15,254 | VTE | Rivaroxaban, apixaban | 3 months | Recurrent VTE, MB | 8 |
Bott-Kitslaar DM, 2019 [20] | Prospective | The Mayo Thrombophilia Clinic Registry between Mar 1, 2013, and Jan 30, 2018 | 600 | VTE | Rivaroxaban, apixaban | 3 months | Recurrent VTE, MB, CRNMB | 9 |
Davis DO, 2017 [21] | Retrospective | Ochsner Medical Center from January 1, 2013, through December 31, 2015 | 37 | VTE | Dabigatran, rivaroxaban, apixaban | 6 months | Recurrent VTE, bleeding | 6 |
López-Núñez JJ, 2019 [22] | Retrospective | Data in the RIETE registry Jan 2013 to Apr 2018 | 1298 | VTE | Dabigatran, rivaroxaban, apixaban, edoxaban | 3 months | Recurrent VTE, MB | 6 |
Lutseya PL, 2019 [23] | Retrospective | Market Scan data warehouse (Truven Health Analytics) for the time-period from Jan 1, 2011 to Dec 31, 2016 | 37,768 | VTE | Rivaroxaban, apixaban | 6 months | Hospitalized bleeding | 7 |
Sindet-Pedersen C, 2018 [18] | Retrospective | Danish nationwide registries from Jan 1, 2015 to Jun 30, 2017 | 8187 | VTE | Rivaroxaban, apixaban | 6 months | All-cause mortality, recurrent VTE, hospitalized bleeding | 7 |
Study | Race | Apixaban | Rivaroxaban | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
No | Age | Gender (M, %) | Renal disease (%) | Antiplatelets (%) | No | Age | Gender (M, %) | Renal disease (%) | Antiplatelets (%) | ||
(b) | |||||||||||
Dawwas GK, 2018 [19] | Caucasian | 3091 | 61.6 ± 16.4 | 49.4 | 17.1 | 7.20 | 12,163 | 59.9 ± 16.2 | 49.6 | 15.3 | 6.50 |
Bott-Kitslaar DM, 2019 [20] | Caucasian | 302 | 62.4 ± 14.0 | 62.3 | 9.00 | 22.5 | 298 | 58.5 ± 14.2 | 52.0 | 4.00 | 20.5 |
Davis DO, 2017 [21] | Caucasian | Total age: 69 ± 4.75, Gender: 45.9% male, antiplatelet 27.0% | |||||||||
López-Núñez JJ, 2019 [22] | Caucasian | Total age: 79 ± 9.9, Gender: 37.0% male, renal disease 41%, antiplatelet 2.0% | |||||||||
Lutsey PL, 2019 [23] | Caucasian | 6786 | 60.4 ± 16.2 | 49.6 | 13.2 | 7.00 | 30,982 | 56.4 ± 15.4 | 51.8 | 7.10 | 5.10 |
Sindet-Pedersen C, 2018 [18] | Caucasian | 1504 | 70.0 ± 17.8 | 49.2 | 3.90 | 15.2 | 6683 | 67.0 ± 17.1 | 54.7 | 2.70 | 12.9 |